Amrutanjan Health Care Limited
NSE: AMRUTANJANMarket Closed • NSE
Day range
52 week range
Amrutanjan Health Care Limited closed at INR513.80 (+1.54%) on volume 0.59x its 20-day average, trading 32.41% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved -16.8% QoQ
2026-09-11
DIVIDEND Announced
Dividend - Rs 2.90 Per Share
2026-02-06
DIVIDEND Announced
Interim Dividend - Re 1 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 31.4%
Low Debt Profile: Debt-to-Equity is comfortable at 0.48x
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 11 Sept 2026 | Dividend | ₹2.90 / share | — | 11 Sept 2026 |
| 07 Feb 2026 | Dividend | ₹1.00 / share | — | 06 Feb 2026 |
| 18 Nov 2025 | Dividend | ₹1.00 / share | — | 18 Nov 2025 |
| 16 Sept 2025 | Dividend | ₹2.60 / share | — | 16 Sept 2025 |
| 18 Feb 2025 | Dividend | ₹1.00 / share | — | 18 Feb 2025 |
| 22 Nov 2024 | Dividend | ₹1.00 / share | — | 22 Nov 2024 |
| 16 Sept 2024 | Dividend | ₹2.60 / share | — | 13 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 13 Sept 2024 |
| 20 Feb 2024 | Dividend | ₹1.00 / share | — | 20 Feb 2024 |
| 23 Nov 2023 | Dividend | ₹1.00 / share | — | 23 Nov 2023 |
| 14 Sept 2023 | Dividend | ₹2.60 / share | — | 14 Sept 2023 |
| 13 Jul 2023 | Buy Back | Buy Back | — | 13 Jul 2023 |
| 24 Feb 2023 | Dividend | ₹1.00 / share | — | 24 Feb 2023 |
| 15 Nov 2022 | Dividend | ₹1.00 / share | — | 14 Nov 2022 |
| — | Dividend | ₹2.60 / share | — | 14 Sept 2022 |
| 21 Feb 2022 | Dividend | ₹1.00 / share | — | 18 Feb 2022 |
| 17 Nov 2021 | Dividend | ₹1.00 / share | — | 16 Nov 2021 |
| 16 Sept 2021 | Dividend | ₹2.60 / share | — | 15 Sept 2021 |
| 19 Feb 2021 | Dividend | ₹0.80 / share | — | 17 Feb 2021 |
| 20 Nov 2020 | Dividend | ₹0.80 / share | — | 19 Nov 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 15 Sept 2020 |
| 21 Feb 2020 | Dividend | ₹1.55 / share | — | 18 Feb 2020 |
| 18 Nov 2019 | Dividend | ₹0.55 / share | — | 15 Nov 2019 |
| — | Dividend | ₹1.05 / share | — | 17 Sept 2019 |
| 21 Feb 2019 | Dividend | ₹0.55 / share | — | 20 Feb 2019 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
IndiaHealthcare
Is Amrutanjan Health Care Limited Shariah compliant?
Amrutanjan Health Care Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.12%) complies with AAOIFI threshold (≤ 33%).
What is Amrutanjan Health Care Limited's current valuation relative to peers?
Amrutanjan Health Care Limited trades at a P/E of 27.5x compared to the sector median of 37x, and a Price-to-Book of 4.0x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.48x. Interest coverage is 316.7x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 14.1% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.